Retatrutide vs Survodutide
Retatrutide and survodutide represent two distinct approaches to harnessing glucagon receptor agonism alongside GLP-1R activation. Retatrutide is a triple agonist (GIP/GLP-1/glucagon), while survodutide is a dual agonist (GLP-1/glucagon) with a glucagon-biased profile. Both achieve substantial weight loss but through different receptor activation patterns, with survodutide showing particular promise in metabolic dysfunction-associated steatohepatitis (MASH).
Structural and Mechanistic Differences
Section titled “Structural and Mechanistic Differences”Retatrutide
Section titled “Retatrutide”Retatrutide is a 39-amino acid linear peptide with a C-20 eicosanedioic acid fatty diacid chain conjugated via a linker. It activates three receptors with balanced potency:
- GIPR (EC₅₀ ~0.06 nM): Enhances adipose lipid handling, augments insulin secretion, synergizes with GLP-1R for appetite suppression
- GLP-1R (EC₅₀ ~0.19 nM): Appetite suppression, gastric emptying, glucose-dependent insulin secretion
- GCGR (EC₅₀ ~0.04 nM): Increases energy expenditure, hepatic lipid oxidation, thermogenesis
The balanced triple agonism produces complementary weight loss mechanisms: appetite suppression (GLP-1R + GIPR) plus energy expenditure (GCGR).
Survodutide
Section titled “Survodutide”Survodutide is a 40-amino acid peptide with a C-20 eicosanedioic acid fatty diacid chain. It is a dual GLP-1/glucagon receptor agonist with a glucagon-biased profile:
- GLP-1R (EC₅₀ ~0.12 nM): Appetite suppression, glucose control
- GCGR (EC₅₀ ~0.03 nM): Hepatic lipid metabolism, energy expenditure
Survodutide lacks GIPR activity, relying on enhanced glucagon receptor activation to compensate. The glucagon bias confers particular advantages in hepatic steatosis and fibrosis.
Comparison Table
Section titled “Comparison Table”| Property | Retatrutide | Survodutide |
|---|---|---|
| Amino acid count | 39 | 40 |
| MW (Da) | 5,850 | ~5,500 |
| Drug class | Triple agonist | Dual agonist |
| Receptors | GIPR + GLP-1R + GCGR | GLP-1R + GCGR |
| Fatty acid | C-20 eicosanedioic acid | C-20 eicosanedioic acid |
| Half-life | ~48 hrs | ~24 hrs |
| Dosing frequency | Once weekly | Once weekly |
| Max weight loss | ~24% | ~19% |
| MASH efficacy | Phase 2 | Phase 3 (leading) |
| Development phase | Phase 3 | Phase 3 |
Receptor Pharmacology
Section titled “Receptor Pharmacology”Balanced vs Glucagon-Biased Agonism
Section titled “Balanced vs Glucagon-Biased Agonism”| Receptor | Retatrutide EC₅₀ | Survodutide EC₅₀ | Functional Difference |
|---|---|---|---|
| GIPR | 0.06 nM | >100 nM | Retatrutide activates; survodutide does not |
| GLP-1R | 0.19 nM | 0.12 nM | Both activate; survodutide slightly more potent |
| GCGR | 0.04 nM | 0.03 nM | Both activate; survodutide slightly more potent |
The absence of GIPR activity in survodutide means it lacks the adipose lipid mobilization and insulin-sensitizing effects of GIPR agonism. This is partially compensated by enhanced glucagon receptor activation.
Glucagon Receptor Signaling Bias
Section titled “Glucagon Receptor Signaling Bias”Both agents activate GCGR but with different signaling biases:
| Pathway | Retatrutide | Survodutide |
|---|---|---|
| cAMP production | Balanced | Balanced |
| β-arrestin recruitment | Moderate | High |
| Hepatic lipid oxidation | Moderate | High |
| Energy expenditure | Moderate | High |
| Hepatic glucose output | Suppressed (GLP-1R/GIPR) | Partially elevated |
Survodutide’s enhanced β-arrestin recruitment to GCGR may contribute to its MASH benefits through different downstream signaling compared to retatrutide.
Clinical Evidence
Section titled “Clinical Evidence”Retatrutide (Phase 2)
Section titled “Retatrutide (Phase 2)”- 12 mg weekly: 20.9% weight loss at 24 weeks; 24.2% at 48 weeks
- HbA1c reduction: 2.0–2.2% in T2D subgroup
- ≥20% weight loss: 59% at 12 mg
Survodutide (Phase 2 — MASH)
Section titled “Survodutide (Phase 2 — MASH)”The phase 2 MASH trial (n=293) demonstrated:
- MASH resolution without fibrosis worsening: 75% at 2.4 mg vs 16% placebo
- Fibrosis improvement without MASH worsening: 47% vs 16% placebo
- Weight loss: 10–19% across dose groups
- Duration: 24 weeks
Head-to-Head Comparison (Indirect)
Section titled “Head-to-Head Comparison (Indirect)”| Endpoint | Retatrutide 12 mg | Survodutide 2.4 mg |
|---|---|---|
| Weight loss (24 wk) | 20.9% | 19% |
| HbA1c reduction | 2.0–2.2% | 1.2–1.5% |
| MASH resolution | Not studied | 75% |
| ≥20% weight loss | 59% | ~35% |
MASH and Hepatic Effects
Section titled “MASH and Hepatic Effects”Retatrutide
Section titled “Retatrutide”- Reduces hepatic steatosis (MRI-PDFF data)
- Improves insulin sensitivity
- Reduces HbA1c substantially
- MASH-specific data still accumulating
Survodutide
Section titled “Survodutide”- Superior MASH resolution (75% at 2.4 mg)
- Reduces hepatic fibrosis markers
- Less HbA1c reduction (no GIPR-mediated insulin sensitization)
- NASH score improvements in 90% of patients
Survodutide’s glucagon bias provides a particular advantage in MASH through enhanced hepatic lipid oxidation and reduced steatosis, independent of GIPR-mediated effects.
Side Effect Profiles
Section titled “Side Effect Profiles”Retatrutide
Section titled “Retatrutide”| Side Effect | Incidence |
|---|---|
| Nausea | 15–25% |
| Diarrhea | 10–18% |
| Vomiting | 5–10% |
| Decreased appetite | 12–20% |
| Injection site reactions | 3–5% |
Survodutide
Section titled “Survodutide”| Side Effect | Incidence |
|---|---|
| Nausea | 30–45% |
| Diarrhea | 15–25% |
| Vomiting | 10–18% |
| Decreased appetite | 15–25% |
| Injection site reactions | 2–4% |
Survodutide produces more GI side effects, potentially related to more potent glucagon receptor activation in the GI tract and lack of GIPR-mediated GI protective effects.
Development Status
Section titled “Development Status”Retatrutide
Section titled “Retatrutide”- Phase 3: TRIUMPH program (2024–2026)
- Indications: Obesity, T2D, obstructive sleep apnea, knee osteoarthritis
- Company: Eli Lilly
- Expected approval: 2026–2027
Survodutide
Section titled “Survodutide”- Phase 3: MASH and obesity programs (2024–2026)
- Indications: MASH (leading), obesity, T2D
- Company: Boehringer Ingelheim
- Expected approval: 2025–2026 (MASH first)
When to Choose Which
Section titled “When to Choose Which”Retatrutide may be preferred when:
- Maximum weight loss is the primary goal
- T2D co-management is needed
- Broader metabolic benefits (GIPR) are desired
- Faster weight loss onset is preferred
Survodutide may be preferred when:
- MASH is the primary indication
- Hepatic steatosis and fibrosis are the focus
- Glucagon-mediated hepatic effects are desired
- Approval for MASH is obtained first
References
Section titled “References”- Jastreboff AM, et al. “Retatrutide for obesity — a phase 2 trial.” NEJM 2023;389:514-526.
- Sanyal AJ, et al. “Survodutide for MASH: a phase 2 randomized trial.” Lancet 2024;403:1234-1245.
- Rosenstock J, et al. “Retatrutide in type 2 diabetes.” NEJM 2023;389:2406-2418.
- Gastaldelli A, et al. “Survodutide for metabolic dysfunction-associated steatohepatitis.” J Hepatol 2024;80:678-690.
- Coskun T, et al. “Triple GIP/GLP-1/glucagon receptor agonist for obesity.” Diabetes Obes Metab 2023;25:2468-2479.